The binding of SH3BGRL to HER2 can also cause a conformational change in the receptor, leading to maintenance of unique tyrosine phosphorylation and promoting the extension of downstream signaling, thereby promoting the proliferation and survival of breast cancer cells [49]. Here, ERBB2 is linked to breast carcinoma.